NCT04648254View on ClinicalTrials.gov

Oral Axl/Mer/CSF1R Selective Tyrosine Kinase Inhibitor in Patients with Advanced Solid Tumor

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

78

Participants

Timeline

Start Date

November 18, 2020

Primary Completion Date

December 31, 2024

Study Completion Date

February 28, 2025

Conditions
Solid TumorAdvanced CancerMetastatic Cancer
Interventions
DRUG

Q702

The study drug Q702 will be administered once daily by mouth on Days 1 through 7 and Days 15 through 21 of every treatment cycle.

Trial Locations (4)

60611

Northwestern University, Chicago

90033

University of Southern California, Los Angeles

90048

Cedars-Sinai Medical Center, Los Angeles

07960

Atlantic Health System Hospital, Morristown

All Listed Sponsors
lead

Qurient Co., Ltd.

INDUSTRY

NCT04648254 - Oral Axl/Mer/CSF1R Selective Tyrosine Kinase Inhibitor in Patients with Advanced Solid Tumor | Biotech Hunter | Biotech Hunter